Hackensack, NJ11 Active Studies

Advanced Solid Tumors Clinical Trials in Hackensack, NJ

Find 11 actively recruiting advanced solid tumors clinical trials in Hackensack, NJ. Connect with local research sites and explore new treatment options.

11
Active Trials
10
Sponsors
3,065
Enrolling

Recruiting Advanced Solid Tumors Studies in Hackensack

RecruitingHackensack, NJNCT06334432

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid...

466 participants
Nuvation Bio Inc.
View Study Details
RecruitingHackensack, NJNCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

413 participants
Bristol-Myers Squibb
View Study Details
RecruitingHackensack, NJNCT06730750

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5....

360 participants
Bristol-Myers Squibb
View Study Details
RecruitingHackensack, NJNCT05684965

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

358 participants
Xilio Development, Inc.
View Study Details
RecruitingHackensack, NJNCT06873789

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors....

322 participants
Incyte Corporation
View Study Details
RecruitingHackensack, NJNCT05584670

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

291 participants
Sanofi
View Study Details
RecruitingHackensack, NJNCT04145622

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

250 participants
Daiichi Sankyo
View Study Details
RecruitingHackensack, NJNCT05533697

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab....

194 participants
ModernaTX, Inc.
View Study Details
RecruitingHackensack, NJNCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumor...

180 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingHackensack, NJNCT06747585

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

170 participants
Alentis Therapeutics AG
View Study Details
RecruitingHackensack, NJNCT05269316

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

61 participants
Impact Therapeutics, Inc.
View Study Details

About Advanced Solid Tumors Clinical Trials in Hackensack

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 11 advanced solid tumors clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 3,065 participants. Research is being sponsored by Nuvation Bio Inc., Bristol-Myers Squibb, Xilio Development, Inc. and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Hackensack — FAQ

Are there advanced solid tumors clinical trials in Hackensack?

Yes, there are 11 advanced solid tumors clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 11 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated March 2, 2026 from ClinicalTrials.gov